Skip to content
Opdualag(relatlimab)
Opdualag (relatlimab) is an antibody pharmaceutical. Relatlimab was first approved as Opdualag on 2022-03-18. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against lymphocyte activation gene 3 protein.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
Trade Name
FDA
EMA
Combinations
Opdualag
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Nivolumab
+
Relatlimab
Tradename
Proper name
Company
Number
Date
Products
Opdualagnivolumab and relatlimab-rmbwBristol-Myers Squibb CompanyN-761234 RX2022-03-18
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
opdualagBiologic Licensing Application2022-03-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanoma—D008545—
Agency Specific
FDA
EMA
Expiration
Code
nivolumab / relatlimab, Opdualag, Bristol-Myers Squibb Company
2029-03-18Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545273——11
Colorectal neoplasmsD015179121——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8077———12
Stomach neoplasmsD013274EFO_0003897C1614———5
Liver neoplasmsD008113EFO_1001513C22.033———5
Squamous cell carcinoma of head and neckD00007719512———3
Uveal neoplasmsD014604EFO_100123012———3
Non-small-cell lung carcinomaD00228912———3
Ovarian neoplasmsD010051EFO_0003893C5612———2
Esophageal neoplasmsD004938C1511———2
Colonic neoplasmsD003110C18—2———2
Non-hodgkin lymphomaD008228C85.922———2
Show 30 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_00005152————2
Brain neoplasmsD001932EFO_0003833C711————1
GliosarcomaD0183161————1
Castration-resistant prostatic neoplasmsD0641291————1
Urologic neoplasmsD014571C64-C681————1
Neoplasm metastasisD009362EFO_00097081————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRELATLIMAB
INNrelatlimab
Description
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3990044
ChEBI ID—
PubChem CID—
DrugBankDB14851
UNII IDAF75XOF6W3 (ChemIDplus, GSRS)
Target
Agency Approved
LAG3
LAG3
Organism
Homo sapiens
Gene name
LAG3
Gene synonyms
FDC
NCBI Gene ID
3902
Protein name
lymphocyte activation gene 3 protein
Protein synonyms
CD223, lymphocyte-activation gene 3
Uniprot ID
Q7Z643
Mouse ortholog
Lag3 (16768)
lymphocyte activation gene 3 protein (Q61790)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Opdualag - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 772 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
130 adverse events reported
View more details